Clinical stage biotech firm Vyriad has entered into a strategic partnership with Novartis to discover and develop chimeric antigen receptor (CAR) T-cell therapies.
The partners will use Vyriad's active targeting lentiviral vector platform and Novartis' expertise in cell therapy innovation to identify and develop in vivo CAR-T cell therapy candidates, which will then be clinically advanced by Novartis, the firms said in a statement.
"Taking an in vivo approach to CAR-T cell therapies has the potential to transform the field," Vyriad CEO Dr. Stephen J. Russell, PhD, said. "We believe our targeted delivery platform is poised to enable this vision for the industry and our collaboration with Novartis represents an exciting step forward in advancing the next generation of CAR-T cell treatments."
Vyriad will receive an upfront payment, milestone payments, and tiered royalties on each program; detailed financial and other terms of the collaboration were not disclosed.
